Literature DB >> 16901920

IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T.

Klaus W Frommer1, Katharina Reichenmiller, Burkhardt S Schutt, Andreas Hoeflich, Michael B Ranke, Gabriele Dodt, Martin W Elmlinger.   

Abstract

There is evidence that insulin-like growth factor-binding protein (IGFBP-2), a modulator of the actions of IGFs, also has IGF-independent effects in human tumor cell lines. These involve specific binding of IGFBP-2 to alpha5beta1-integrin, followed by alterations in the phosphorylation status of downstream signaling molecules. Previously, IGFBP-2 has also been shown to be associated with cell proliferation, adhesion and migration. Here, we investigated direct effects of IGFBP-2 on apoptosis and alterations in the expression of related proteins. The breast cancer cell line Hs578T, which shows no IGFBP-2 production of its own and is independent of the IGF-I receptor, was treated with human recombinant IGFBP-2 in order to study the changes in gene expression induced by IGFBP-2. The methods employed for this purpose were oligonucleotide microarrays, real-time RT-PCR, western blotting, and immunoassays. Out of the 440 genes covered by the Oligo GEArray Human Cancer Microarray OHS-802, the expression of 77 genes was directly influenced by IGFBP-2. By the use of real-time quantitative RT-PCR, the gene expression of Nuclear Factor (NF)kappaB, p53, transforming growth factor beta (TGF beta-1), LAMB1 (Laminin, Beta 1), Bcl-2, and IIp45 was found to be significantly upregulated (by 1.2- to 3.05-fold; all P < 0.001). Accordingly, NFkappaB, p53, and TGF beta-1 proteins, as measured by Western blotting and immunoassay, were upregulated > 1.5-fold. By using an ELISA-based and a flow cytometry-based apoptosis assay, IGFBP-2 was found to have a pro-apoptotic effect on Hs578T cells. Our results suggest that IGFBP-2-induced gene expressions are of functional significance for proliferation, cell adhesion, cell migration and apoptosis, and showed that IGFBP-2 can promote apoptosis in tumor cells independent of IGF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901920     DOI: 10.1677/jme.1.01955

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  29 in total

1.  Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.

Authors:  Chad P Garner; Yuan C Ding; Esther M John; Sue A Ingles; Olufunmilayo I Olopade; Dezheng Huo; Clement Adebamowo; Temidayo Ogundiran; Susan L Neuhausen
Journal:  Hum Genet       Date:  2008-01-22       Impact factor: 4.132

2.  IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology.

Authors:  James Beattie; Yousef Hawsawi; Hanaa Alkharobi; Reem El-Gendy
Journal:  J Cell Commun Signal       Date:  2015-02-03       Impact factor: 5.782

3.  BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.

Authors:  Fan Wang; Liyang Zhang; Buqing Sai; Lujuan Wang; Xina Zhang; Leliang Zheng; Jiuqi Tang; Guiyuan Li; Juanjuan Xiang
Journal:  Cancer Biol Ther       Date:  2019-09-27       Impact factor: 4.742

Review 4.  Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Authors:  Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras
Journal:  Crit Rev Oncog       Date:  2015

5.  Serum IGF-binding protein 2 (IGFBP-2) concentrations change early after gastric bypass bariatric surgery revealing a possible marker of leptin sensitivity in obese subjects.

Authors:  Giovanni Ceccarini; Caterina Pelosini; Federica Ferrari; Silvia Magno; Jacopo Vitti; Guido Salvetti; Carlo Moretto; Antonio Marioni; Piero Buccianti; Paolo Piaggi; Margherita Maffei; Ferruccio Santini
Journal:  Endocrine       Date:  2019-04-03       Impact factor: 3.633

6.  A model to explain specific cellular communications and cellular harmony:- a hypothesis of coupled cells and interactive coupling molecules.

Authors:  Cyril J Craven
Journal:  Theor Biol Med Model       Date:  2014-09-14       Impact factor: 2.432

7.  Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.

Authors:  Kristen M Holmes; Matti Annala; Corrine Y X Chua; Sarah M Dunlap; Yuexin Liu; Niek Hugen; Lynette M Moore; David Cogdell; Limei Hu; Matti Nykter; Kenneth Hess; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-15       Impact factor: 11.205

8.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

9.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.

Authors:  Kenichi Miyako; Laura J Cobb; Malik Francis; Alden Huang; Bonnie Peng; John E Pintar; Hiroyoshi Ariga; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2008-12-18

10.  Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.

Authors:  Susan L Neuhausen; Sean Brummel; Yuan Chun Ding; Christian F Singer; Georg Pfeiler; Henry T Lynch; Katherine L Nathanson; Timothy R Rebbeck; Judy E Garber; Fergus Couch; Jeffrey Weitzel; Steven A Narod; Patricia A Ganz; Mary B Daly; Andrew K Godwin; Claudine Isaacs; Olufunmilayo I Olopade; Gail Tomlinson; Wendy S Rubinstein; Nadine Tung; Joanne L Blum; Daniel L Gillen
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.